Cardiff Oncology Stock Performance
| CRDF Stock | USD 2.64 0.27 11.39% |
On a scale of 0 to 100, Cardiff Oncology holds a performance score of 3. The firm shows a Beta (market volatility) of 2.43, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cardiff Oncology will likely underperform. Please check Cardiff Oncology's sortino ratio, semi variance, rate of daily change, as well as the relationship between the value at risk and kurtosis , to make a quick decision on whether Cardiff Oncology's price patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cardiff Oncology are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak fundamental indicators, Cardiff Oncology reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 11.39 | Five Day Return (34.98) | Year To Date Return (38.03) | Ten Year Return (99.53) | All Time Return (99.84) |
Last Split Factor 1:6 | Dividend Date 2019-02-20 | Last Split Date 2019-02-20 |
1 | Cardiff Oncology Stock Reacts to Delayed Clinical Data Update CRDF Stock News | 06/18/2025 |
2 | This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note Here Are Top 4 Initiations For Tuesday | 06/24/2025 |
3 | Acquisition by Pace Gary W of 40565 shares of Cardiff Oncology at 3.16 subject to Rule 16b-3 | 06/26/2025 |
4 | Cardiff Oncology Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity - Seeking Alpha | 06/27/2025 |
5 | Cardiff Oncology Receives New Coverage with Buy Rating CRDF Stock News | 07/08/2025 |
6 | What analysts say about Cardiff Oncology Inc. stock - Exceptional stock performance - jammulinksnews.com | 07/22/2025 |
7 | Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update | 07/29/2025 |
8 | Cardiff Oncology Q2 Loss Down 19 | 07/30/2025 |
9 | Gary W. Pace Buys 15,000 Shares of Cardiff Oncology, Inc. Stock | 08/01/2025 |
| Begin Period Cash Flow | 21.7 M | |
| Total Cashflows From Investing Activities | 13.7 M |
Cardiff Oncology Relative Risk vs. Return Landscape
If you would invest 255.00 in Cardiff Oncology on May 6, 2025 and sell it today you would earn a total of 9.00 from holding Cardiff Oncology or generate 3.53% return on investment over 90 days. Cardiff Oncology is currently generating 0.264% in daily expected returns and assumes 6.3132% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Cardiff, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cardiff Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cardiff Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cardiff Oncology, and traders can use it to determine the average amount a Cardiff Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0418
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CRDF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.31 actual daily | 56 56% of assets are less volatile |
Expected Return
| 0.26 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Cardiff Oncology is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cardiff Oncology by adding it to a well-diversified portfolio.
Cardiff Oncology Fundamentals Growth
Cardiff Stock prices reflect investors' perceptions of the future prospects and financial health of Cardiff Oncology, and Cardiff Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cardiff Stock performance.
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.48 | ||||
| Operating Margin | (122.12) % | ||||
| Current Valuation | 107.19 M | ||||
| Shares Outstanding | 66.53 M | ||||
| Price To Earning | (0.48) X | ||||
| Price To Book | 3.02 X | ||||
| Price To Sales | 322.25 X | ||||
| Revenue | 683 K | ||||
| Gross Profit | (40.86 M) | ||||
| EBITDA | (48.25 M) | ||||
| Net Income | (45.43 M) | ||||
| Cash And Equivalents | 122.01 M | ||||
| Cash Per Share | 2.82 X | ||||
| Total Debt | 1.52 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 15.02 X | ||||
| Book Value Per Share | 0.88 X | ||||
| Cash Flow From Operations | (37.69 M) | ||||
| Earnings Per Share | (0.87) X | ||||
| Market Capitalization | 175.63 M | ||||
| Total Asset | 97.19 M | ||||
| Retained Earnings | (384.18 M) | ||||
| Working Capital | 81.63 M | ||||
| Current Asset | 16.9 M | ||||
| Current Liabilities | 4.78 M | ||||
About Cardiff Oncology Performance
By analyzing Cardiff Oncology's fundamental ratios, stakeholders can gain valuable insights into Cardiff Oncology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cardiff Oncology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cardiff Oncology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -11.9 K | -11.3 K | |
| Return On Tangible Assets | (0.47) | (0.49) | |
| Return On Capital Employed | (0.58) | (0.55) | |
| Return On Assets | (0.47) | (0.49) | |
| Return On Equity | (0.55) | (0.58) |
Things to note about Cardiff Oncology performance evaluation
Checking the ongoing alerts about Cardiff Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cardiff Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cardiff Oncology had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 683 K. Net Loss for the year was (45.43 M) with loss before overhead, payroll, taxes, and interest of (40.86 M). | |
| Cardiff Oncology currently holds about 122.01 M in cash with (37.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.82, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cardiff Oncology has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Gary W. Pace Buys 15,000 Shares of Cardiff Oncology, Inc. Stock |
- Analyzing Cardiff Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cardiff Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Cardiff Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cardiff Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cardiff Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cardiff Oncology's stock. These opinions can provide insight into Cardiff Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cardiff Stock analysis
When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |